From the Journals

World first: Saliva test detects occult HPV-driven oropharyngeal cancer


 

Long-term persistence

As researchers explained in their paper, long-term persistence of HPV-16 infection is most likely a prerequisite for the development of subsequent malignancy.

Unlike cervical cancer caused by HPV-16 infection, the natural history of HPV infection in the oropharyngeal cavity is not known.

However, clinical assessment of patients with either persistent HPV infection or microscopic carcinoma has failed to detect any identifiable abnormalities.

Thus, this is the first report of a histologically confirmed diagnosis of an asymptomatic occult oropharyngeal cancer detected by a screening test through serial measurements of HPV-16 DNA, the investigators emphasized.

The report also demonstrated that very early lesions can be eradicated with minimal morbidity. Unfortunately, most oropharyngeal cancer is currently diagnosed at much later stages, and surgical removal of these is often associated with significant disabilities including difficulties with swallowing and even communicating.

“It’s amazing to think that this man was cured of his disease with a 15-minute procedure which left him with no lasting issues at all,” Dr. Punyadeera commented. “We need to try and make this the norm, not the exception.

“So we must have a well-designed screening study using all the insights we have gained from this case. We owe it to patients to explore these findings to their fullest,” Dr. Punyadeera emphasized.

The authors have disclosed no relevant financial relationships.

This article first appeared on Medscape.com.

Pages

Recommended Reading

Will coronavirus restrictions lead to more advanced cancers?
MDedge Hematology and Oncology
ASCO panel outlines cancer care challenges during COVID-19 pandemic
MDedge Hematology and Oncology
COVID-19: Defer ‘bread and butter’ procedure for thyroid nodules
MDedge Hematology and Oncology
Metastatic cancer linked to worse outcomes of COVID-19
MDedge Hematology and Oncology
Antitumor treatment may increase risk of severe events in COVID-19 patients
MDedge Hematology and Oncology
Excess cancer deaths predicted as care is disrupted by COVID-19
MDedge Hematology and Oncology
COVID-19 death rate was twice as high in cancer patients in NYC study
MDedge Hematology and Oncology
FDA approves selpercatinib for lung and thyroid RET tumors
MDedge Hematology and Oncology
ASCO goes ahead online, as conference center is used as hospital
MDedge Hematology and Oncology
Video coaching may relieve anxiety and distress for long-distance cancer caregivers
MDedge Hematology and Oncology